1. Canada Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
HYTN Innovations Inc

HYTN Innovations Inc

0.15
CAD
+0.03
(+25.00%)
-0.02EPS
17.26MMarket Cap
2019 Y
2020 Y
2021 Y
2021 Y
2022 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.02
0.01
0.01
0.02
0.04
Basic EPS, GAAP
-0.01
- -
- -
-0.01
-0.01
-0.23
-0.04
-0.09
-0.02
-0.02
Free Cash Flow per Basic Share
-0.01
-0.01
- -
-0.03
- -
-0.05
-0.02
-0.01
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.01
-0.03
- -
-0.03
0.03
0.01
- -
-0.01
-0.02
Tangible Book Value per Share
0.01
0.01
-0.03
- -
-0.03
0.03
0.01
- -
-0.01
-0.02
Basic Weighted Avg Shares
62
62
62
62
62
44
62
75
93
94
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
1
1
1
2
4
Operating Margin (%)
- -
- -
- -
- -
- -
-435.92
-280.5
-312.71
-81.91
-34.97
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-1
- -
-10
-2
-7
-2
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-1,475.34
-305.78
-776.81
-90.63
-46.9
Working Capital
- -
- -
-2
-2
-2
1
- -
-1
-1
-2
LT Debt
- -
- -
- -
1
- -
1
1
1
1
1
Total Equity
- -
1
-2
- -
-2
2
- -
- -
-1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-44.23
- -
- -
- -
- -
-195.46
- -
- -
- -

Capital Structure

CAD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
94
96
96
Market Capitalization
19
23
17

Working Capital

CAD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
- -
1
Inventories
1
1
- -
Total Current Liabilities
3
3
3
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4,760.63%
547.53%
Free Cash Flow
- -
121.94%
-25.78%
Net Income, GAAP
- -
565.27%
-77.06%
Sales/Revenue/Turnover
- -
- -
96.58%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
1
2
2026
1
- -
1
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.01
- -
-0.06
-0.09
2025
-0.01
- -
- -
- -
-0.02
2026
- -
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Elliot McKerr
Full Time Employees
7
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Unit 303 - 890 Clement Ave Kelowna BC Canada V1Y 7E4
IPO Date
Aug 29, 1997
Website
hytn.ca
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
HYTN Innovations Inc. formulates, manufactures, markets, and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybin, with a focus on pharmaceutical-grade GMP manufacturing for global markets; core offerings encompass Elevation Technology nano-emulsions for beverages and edibles, sparkling cannabis beverages such as Rosewater Lemonade, Watermelon Mint, Lemongrass Ginger, and Blood Orange, dry flower processing, solventless extracts, non-solid extracts, cannabis vapes in 510 cartridges, live resin API, bulk dry flower API, bulk dry psilocybin mushroom API, bulk solventless extraction API, final packaged cannabis goods in jars and bags, bulk cannabis packaging, and GMP-processed psilocybin mushrooms in sachets and bags. The company operates a GMP-licensed facility in Kelowna, British Columbia, Canada, founded in 2015 and headquartered at 890 Clement Avenue Suite 303, with geographic reach spanning domestic sales in Canadian provinces including Ontario, Quebec, Alberta, British Columbia, Nova Scotia, Manitoba, Yukon, and the Northwest Territories, alongside international exports to Australia, the United Kingdom, and Germany. Recent developments include the completion of the Prism Scientific Labs acquisition in July 2024 to enhance psychedelic compound manufacturing, initial purchase orders under a January 2025 manufacturing partnership with SNDL Inc., a February 2025 collaboration with A1 Cannabis Inc. to integrate Summit Cannabis Beverages and expand beverage operations, securing additional UK import/export permits and opening orders from 4C Labs for GMP cannabis products, expanded GMP certifications for distribution activities, OTC Pink listing as HYTNF in July 2024, and a non-brokered private placement closing in 2024 raising approximately $749,000.

Company News

Company News APIChatGPT

  • globenewswire.com

    HYTN Announces Extension of Marketing Program

  • globenewswire.com

    HYTN Announces Proposed Spin-Out of BPC-157 Peptide Drug Development Business